For roughly two decades, the conversation around GLP-1 receptor agonists in clinical practice centered on a fairly narrow value proposition: glycemic control in type 2 diabetes, with weight reduction as a welcome secondary effect. That framing is now obsolete. The publication of the SELECT trial in late 2023 [5] shifted the clinical rationale for semaglutide — and by extension, the broader class of incretin-based peptides — from metabolic management into the domain of primary and secondary cardiovascular prevention. For clinic owners running metabolic and functional medicine practices, this is not a subtle academic update. It is a repositioning of an entire therapeutic category, and it changes the conversation practitioners should be having with patients who present with elevated cardiometabolic risk but no diabetes diagnosis.
The implications extend beyond prescribing decisions. They affect how research protocols are structured, how outcomes are tracked, how patient education is delivered, and how clinics justify long-term therapy in populations that historically fell into the gap between 'not sick enough' for cardiology and 'not diabetic enough' for endocrinology. This article unpacks what the cardiovascular outcomes trial (CVOT) data actually shows, where the mechanistic story holds up, and what it means for practices working with research-grade peptides under physician-supervised protocols.
What Is Semaglutide and Why Does It Have Cardiovascular Signal?
Semaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. Structurally, it is a 31-amino-acid analog of native GLP-1 with substitutions at positions 8 (Aib) and 34 (Arg), plus a C18 fatty diacid moiety attached via a linker at position 26. That fatty acid chain enables reversible albumin binding, which is what extends the half-life to approximately one week and permits once-weekly dosing. It is synthesized via solid-phase peptide synthesis followed by semi-recombinant assembly and lipidation.
Mechanistically, semaglutide binds the GLP-1 receptor, a class B G-protein-coupled receptor expressed on pancreatic beta cells, hypothalamic neurons (particularly in the arcuate nucleus), gastric smooth muscle, cardiomyocytes, vascular endothelium, and immune cells. The downstream effects are pleiotropic: glucose-dependent insulin secretion, suppression of glucagon, delayed gastric emptying, and — critically for the CVOT conversation — direct effects on endothelial function, inflammatory signaling, and myocardial energetics.
The cardiovascular signal, in other words, was never purely a consequence of weight loss. GLP-1 receptors on vascular endothelium modulate nitric oxide bioavailability. Signaling through these receptors appears to blunt NF-κB-driven inflammatory cascades and reduce vascular smooth muscle proliferation. This mechanistic plausibility is why cardiologists took the SELECT hypothesis seriously in the first place — and why the trial was designed the way it was.
The Research: What SELECT and STEP Actually Showed
STEP 1 — Establishing the Weight Loss Baseline
Before SELECT can be understood, the STEP program has to be. STEP 1 enrolled 1,961 adults with a BMI ≥ 30 (or ≥ 27 with a weight-related comorbidity) and no diabetes, randomizing them to once-weekly semaglutide 2.4 mg or placebo for 68 weeks alongside lifestyle intervention [2]. The mean body weight change was −14.9% in the semaglutide arm versus −2.4% in the placebo arm, a treatment difference of approximately 12.4 percentage points. Roughly 86% of semaglutide-treated participants achieved ≥5% weight reduction; over 30% achieved ≥20%. These are effect sizes that had not previously been seen with pharmacotherapy in a non-diabetic obesity population.
The STEP 1 extension study is where the durability question gets interesting — and sobering [1]. When semaglutide was withdrawn at week 68, participants regained approximately two-thirds of their prior weight loss by week 120, and cardiometabolic improvements (systolic blood pressure, lipid parameters, HbA1c, C-reactive protein) largely reverted toward baseline. This is not a failure of the molecule; it is a demonstration that obesity is a chronic disease requiring chronic therapy. For clinics, the practical lesson is that discontinuation planning is a clinical event, not a graduation.
SELECT — The Cardiovascular Outcomes Trial
SELECT was the trial that changed the field [5]. It enrolled 17,604 adults aged ≥45 years with pre-existing cardiovascular disease and a BMI ≥ 27, but crucially without diabetes. Participants were randomized to semaglutide 2.4 mg weekly or placebo and followed for a mean of 39.8 months. The primary composite endpoint was major adverse cardiovascular events (MACE): cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke.
The result: a 20% relative risk reduction in MACE (HR 0.80; 95% CI 0.72–0.90; p<0.001). The number needed to treat was approximately 67 over roughly three years. That is a magnitude of cardiovascular benefit comparable to what statins produce in secondary prevention populations — and it was observed on top of guideline-directed medical therapy, meaning the majority of participants were already on statins, antiplatelets, and antihypertensives.
Two features of SELECT deserve editorial emphasis. First, the cardiovascular curves began separating within the first several months, well before the maximum weight loss was achieved. This strongly suggests that the mechanism of benefit is not reducible to adiposity reduction alone — inflammatory, endothelial, and potentially direct cardiac effects are contributing. Second, the benefit was observed in a population without diabetes. This is the population that has, until now, been undertreated by cardiology because their absolute risk did not meet the threshold for aggressive intervention.
The Safety Signal
A comprehensive safety review of semaglutide across the SUSTAIN, PIONEER, and STEP programs found the adverse event profile to be dominated by gastrointestinal effects — nausea, vomiting, diarrhea, constipation — largely mild to moderate and concentrated during dose escalation [4]. Rates of pancreatitis, medullary thyroid carcinoma, and diabetic retinopathy have been scrutinized; the absolute signal for pancreatitis and MTC remains low and has not translated into a clinically prohibitive concern in the trial populations. Retinopathy progression has been observed in patients with pre-existing diabetic retinopathy undergoing rapid glycemic correction, which is a mechanism-specific concern rather than a general one.
The JAMA obesity management review published in 2023 [3] situated these findings within the broader treatment landscape, noting that pharmacotherapy for obesity should be conceptualized as chronic disease management analogous to hypertension or dyslipidemia — with the expectation of long-term therapy, tolerability monitoring, and dose adjustment rather than short courses aimed at a target weight.
Clinical Considerations for Research Protocols
For practitioners running physician-supervised research protocols with GLP-1 peptides, the CVOT data reshapes several practical considerations. First is patient selection. The historical framing — 'we use this for weight loss' — undersells what the molecule is doing and understates the risk profile of the appropriate patient. A better framing is that GLP-1 receptor agonism is being studied in the context of cardiometabolic risk reduction in populations with elevated BMI and one or more risk factors, with weight change as one biomarker among several.
Second is titration. The tolerability data across STEP and SELECT reinforces the importance of slow dose escalation. The standard schedule — 0.25 mg weekly for four weeks, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg — exists because it minimizes GI adverse events and improves retention. Clinics that compress this schedule to accelerate weight loss trade tolerability for speed, and the discontinuation data suggests that early dropouts do not recapture the metabolic benefit.
Third is monitoring. Given the STEP 1 extension findings on rebound [1], protocols should build in structured reassessment at 6, 12, and 24 months, tracking not just weight but blood pressure, lipid panel, HbA1c, hs-CRP, and — where appropriate — cardiac imaging or advanced lipid markers. Documenting the trajectory of these biomarkers is what allows a practice to have a defensible clinical rationale for continued therapy.
Fourth is discontinuation planning. If a patient does need to come off therapy, the evidence indicates that lifestyle intervention alone will not preserve most of the benefit. Bridging strategies, dose reduction rather than abrupt cessation, and clear discussion of expectations should be part of every intake conversation — not an afterthought at the end of a protocol.
What to Look for in a Research-Grade Source
The peptide supply landscape has expanded dramatically, and not all of that expansion has been quality-driven. For clinics sourcing semaglutide and related GLP-1 analogs for research protocols, several documentation standards should be non-negotiable.
Purity should be verified at ≥99% by reverse-phase HPLC, with a certificate of analysis (COA) that is batch-specific and dated within a reasonable proximity to the manufacturing lot. Mass spectrometry confirmation of molecular weight should accompany HPLC. Endotoxin testing (LAL assay) should demonstrate levels below pharmacopeial thresholds. Residual solvent analysis, particularly for TFA (trifluoroacetic acid, a common byproduct of solid-phase synthesis), should be documented — residual TFA has been associated with immunogenicity concerns in preclinical work.
cGMP manufacturing is the baseline expectation, not a premium feature. A supplier who cannot produce facility certifications, batch records, and independent third-party COA verification is not a research-grade source regardless of what the label claims. Chain-of-custody documentation from synthesis to lyophilization to final vial fill should be traceable. Storage and shipping temperature logs matter — semaglutide is stable but not indestructible, and lyophilized peptide exposed to prolonged ambient conditions during transit is a different molecule than what left the manufacturer.
Reconstitution guidance, stability data post-reconstitution, and clear labeling that the material is intended for physician-supervised research protocols are the final documentation layer. Practices that treat sourcing as a commodity decision are exposing themselves to variability that undermines the reproducibility of their own clinical outcomes.
Why This Matters for Your Practice
The SELECT data is not just a clinical update. It is a strategic inflection point for metabolic and functional medicine practices. Three implications are worth naming directly.
First, the addressable patient population has expanded. Prior to SELECT, the clinical case for GLP-1 therapy in a non-diabetic patient rested primarily on weight and quality-of-life endpoints. That case was defensible but always susceptible to the 'cosmetic' framing that insurance carriers and skeptical patients used to dismiss it. The cardiovascular outcomes data reframes therapy as risk reduction in a population that cardiology has historically underserved. A 55-year-old patient with BMI 29, a prior MI, and no diabetes is now a candidate under a clinical rationale that did not exist eighteen months ago.
Second, the value proposition to patients has changed. Practices that continue to market GLP-1 protocols primarily on the basis of weight loss are underselling what they are actually offering and competing on the wrong axis. The clinics that will differentiate over the next three years are those that position themselves around comprehensive cardiometabolic risk reduction — with structured biomarker tracking, cardiovascular risk assessment, and long-term therapeutic relationships. That is a defensible, higher-margin, and more clinically satisfying practice model than transactional weight loss.
Third, the durability question is a business model question. The STEP 1 extension data [1] makes clear that discontinuation is followed by regression. Practices need to decide whether they are structured to support multi-year therapeutic relationships or whether they are optimized for short courses. The former requires infrastructure — recall systems, ongoing labs, patient education, adverse event management — but it aligns with the biology of the disease and with what the CVOT data implies about appropriate duration of therapy.
The clinics that will differentiate over the next three years are those that position themselves around comprehensive cardiometabolic risk reduction — not transactional weight loss.
The CVOT era of peptide therapy has arrived earlier than most of the field expected. The practices that internalize what SELECT actually demonstrated — a mechanism-driven cardiovascular benefit independent of weight, in a population without diabetes, on top of standard care — will be positioned to lead the conversation with patients, referring providers, and the broader medical community. The ones that continue to treat semaglutide as a weight loss product will find themselves increasingly out of step with where the evidence, and the market, are heading.